{"pmid":32389784,"title":"Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays.","text":["Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays.","In order to fight the SARS-CoV-2 pandemic infection, there is a growing need and demand for diagnostic tools that are complementary and different from the RT-PCR currently in use. Multiple serological tests are or will be very soon available but need to be evaluated and validated. We have thus tested 4 immunochromatographic tests for the detection of antibodies to SARS-CoV-2. In addition, we assessed the kinetics of antibody appearance using these assays in 22 patients after they were tested positive by RT-PCR. We observed great heterogeneity in antiboy detection post-symptom onset. The median antibody detection time was between 8 and 10 days according to the manufacturers. All the tests showed a sensitivity of 60 to 80% on day 10 and 100% on day 15. In addition, a single cross-reaction was observed with other human coronavirus infections. Thus, immunochromatographic tests for the detection of anti-SARS-CoV-2 antibodies may have their place for the diagnostic panel of COVID-19.","J Infect","Demey, Baptiste","Daher, Nagib","Francois, Catherine","Lanoix, Jean-Philippe","Duverlie, Gilles","Castelain, Sandrine","Brochot, Etienne","32389784"],"abstract":["In order to fight the SARS-CoV-2 pandemic infection, there is a growing need and demand for diagnostic tools that are complementary and different from the RT-PCR currently in use. Multiple serological tests are or will be very soon available but need to be evaluated and validated. We have thus tested 4 immunochromatographic tests for the detection of antibodies to SARS-CoV-2. In addition, we assessed the kinetics of antibody appearance using these assays in 22 patients after they were tested positive by RT-PCR. We observed great heterogeneity in antiboy detection post-symptom onset. The median antibody detection time was between 8 and 10 days according to the manufacturers. All the tests showed a sensitivity of 60 to 80% on day 10 and 100% on day 15. In addition, a single cross-reaction was observed with other human coronavirus infections. Thus, immunochromatographic tests for the detection of anti-SARS-CoV-2 antibodies may have their place for the diagnostic panel of COVID-19."],"journal":"J Infect","authors":["Demey, Baptiste","Daher, Nagib","Francois, Catherine","Lanoix, Jean-Philippe","Duverlie, Gilles","Castelain, Sandrine","Brochot, Etienne"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389784","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jinf.2020.04.033","keywords":["antibody","covid-19","lateral flow assay","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666528580106977281,"score":9.490897,"similar":[{"pmid":32504735,"title":"Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.","text":["Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.","OBJECTIVES: SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. METHODS: In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA. RESULTS: Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell(R) POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon). CONCLUSIONS: The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.","J Infect","Tuaillon, E","Bollore, K","Pisoni, A","Debiesse, S","Renault, C","S, Marie","S, Groc","C, Niels","N, Pansu","Am, Dupuy","D, Morquin","V, Foulongne","A, Bourdin","V, Le Moing","P, Van de Perre","32504735"],"abstract":["OBJECTIVES: SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. METHODS: In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA. RESULTS: Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell(R) POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon). CONCLUSIONS: The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved."],"journal":"J Infect","authors":["Tuaillon, E","Bollore, K","Pisoni, A","Debiesse, S","Renault, C","S, Marie","S, Groc","C, Niels","N, Pansu","Am, Dupuy","D, Morquin","V, Foulongne","A, Bourdin","V, Le Moing","P, Van de Perre"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504735","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.077","keywords":["covid-19","elisa","sars-cov-2 antibodies","point of care tests"],"topics":["Diagnosis"],"weight":1,"_version_":1668892488220278784,"score":373.76544},{"pmid":32387968,"title":"Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","text":["Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.","J Clin Virol","Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya","32387968"],"abstract":["BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19."],"journal":"J Clin Virol","authors":["Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387968","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104393","keywords":["covid-19","chest ct scan","immunochromatographic assay","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892589588482,"score":364.45828},{"pmid":32283141,"pmcid":"PMC7195339","title":"Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","text":["Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.","J Infect","Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong","32283141"],"abstract":["An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application."],"journal":"J Infect","authors":["Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283141","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.051","keywords":["colloidal gold-based","covid-19","immunochromatographic strip","real-time rt-pcr","sars-cov-2","serology"],"locations":["Wuhan","China","ICG strip"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491462877186,"score":361.7753},{"pmid":32428207,"title":"Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.","text":["Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19). Polymerase chain reaction (PCR) based tests are optimal and recommended for the diagnosis of an acute SARS-CoV-2 infection. Serology tests for viral antibodies provide an important tool to diagnose previous exposure to the virus. Here we evaluate the analytical performance parameters of the Diazyme SARS-CoV-2 IgM/IgG serology assays and describe the kinetics of IgM and IgG seroconversion observed in patients with PCR confirmed COVID-19 who were admitted to our hospital. METHODS: We validated the performance of the Diazyme assay in 235 subjects to determine specificity. Subsequently, we evaluated the SARS-CoV-2 IgM and IgG seroconversion of 54 PCR confirmed COVID-19 patients and determined sensitivity of the assay at three different timeframes. RESULT: Sensitivity and specificity for detecting seropositivity at >/= 15 days following a positive SARS-CoV-2 PCR result, was 100.0% and 98.7% when assaying for the panel of IgM and IgG. The median time to seropositivity observed for a reactive IgM and IgG result from the date of a positive PCR was 5 days (IQR: 2.75-9 days) and 4 days (IQR: 2.75-6.75 days), respectively. CONCLUSIONS: Our data demonstrates that the Diazyme IgM/IgG assays are suited for the purpose of detecting SARS-CoV-2 IgG and IgM in patients with suspected SARS-CoV-2 infections. For the first time, we report longitudinal data showing the evolution of seroconversion for both IgG and IgM in a cohort of acutely ill patients in the United States. We also demonstrate a low false positive rate in patients who were presumed to be disease free.","J Appl Lab Med","Suhandynata, Raymond T","Hoffman, Melissa A","Kelner, Michael J","McLawhon, Ronald W","Reed, Sharon L","Fitzgerald, Robert L","32428207"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19). Polymerase chain reaction (PCR) based tests are optimal and recommended for the diagnosis of an acute SARS-CoV-2 infection. Serology tests for viral antibodies provide an important tool to diagnose previous exposure to the virus. Here we evaluate the analytical performance parameters of the Diazyme SARS-CoV-2 IgM/IgG serology assays and describe the kinetics of IgM and IgG seroconversion observed in patients with PCR confirmed COVID-19 who were admitted to our hospital. METHODS: We validated the performance of the Diazyme assay in 235 subjects to determine specificity. Subsequently, we evaluated the SARS-CoV-2 IgM and IgG seroconversion of 54 PCR confirmed COVID-19 patients and determined sensitivity of the assay at three different timeframes. RESULT: Sensitivity and specificity for detecting seropositivity at >/= 15 days following a positive SARS-CoV-2 PCR result, was 100.0% and 98.7% when assaying for the panel of IgM and IgG. The median time to seropositivity observed for a reactive IgM and IgG result from the date of a positive PCR was 5 days (IQR: 2.75-9 days) and 4 days (IQR: 2.75-6.75 days), respectively. CONCLUSIONS: Our data demonstrates that the Diazyme IgM/IgG assays are suited for the purpose of detecting SARS-CoV-2 IgG and IgM in patients with suspected SARS-CoV-2 infections. For the first time, we report longitudinal data showing the evolution of seroconversion for both IgG and IgM in a cohort of acutely ill patients in the United States. We also demonstrate a low false positive rate in patients who were presumed to be disease free."],"journal":"J Appl Lab Med","authors":["Suhandynata, Raymond T","Hoffman, Melissa A","Kelner, Michael J","McLawhon, Ronald W","Reed, Sharon L","Fitzgerald, Robert L"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428207","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/jalm/jfaa079","keywords":["covid-19","sars-cov-2","antibody","diagnosis","serology"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728708317184,"score":359.65985},{"pmid":32425648,"pmcid":"PMC7233230","title":"A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.","text":["A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.","In this study, we aimed to evaluate the diagnostic value of serological assay for SARS-CoV-2. A newly-developed ELISA assay for IgM and IgG antibodies against N protein of SARS-CoV-2 was used to screen the serums of 238 admitted hospital patients between February 6 and February 14, 2020 with confirmed or suspected SARS-CoV-2. SARS-CoV-2 RNA was detected on pharyngeal swab specimens using real time RT-PCR. 194 (81.5%) of the serums were detected to be antibody (IgM and/or IgG) positive, significantly higher than the positive rate of viral RNA (64.3%). There was no difference in the positive rate of antibodies between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85), whose nucleic acid tests were negative. The antibody positive rates were very low in the first five days after initial onset of symptoms, and then rapidly increased as the disease progressed. After 10 days, the antibody positive rates jumped from below 50% to over 80%. However, the positive rates of viral RNA maintained above 60% in the first 11 days after initial onset of symptoms, and then rapidly decreased. Overall, the suspected patients were most likely infected by SARS-CoV-2. Before the 11th day after initial onset of symptoms, nucleic acid test is key for confirmation of viral infection. The combination of serological assay can greatly improve the diagnostic efficacy. After the 11th day post-disease onset, the diagnosis for viral infection should be majorly dependent on serological assay.","Microbes Infect","Liu, Lei","Liu, Wanbing","Zheng, Yaqiong","Jiang, Xiaojing","Kou, Guomei","Ding, Jinya","Wang, Qiongshu","Huang, Qianchuan","Ding, Yinjuan","Ni, Wenxu","Wu, Wanlei","Tang, Shi","Tan, Li","Hu, Zhenhong","Xu, Weitian","Zhang, Yong","Zhang, Bo","Tang, Zhongzhi","Zhang, Xinhua","Li, Honghua","Rao, Zhiguo","Jiang, Hui","Ren, Xingfeng","Wang, Shengdian","Zheng, Shangen","32425648"],"abstract":["In this study, we aimed to evaluate the diagnostic value of serological assay for SARS-CoV-2. A newly-developed ELISA assay for IgM and IgG antibodies against N protein of SARS-CoV-2 was used to screen the serums of 238 admitted hospital patients between February 6 and February 14, 2020 with confirmed or suspected SARS-CoV-2. SARS-CoV-2 RNA was detected on pharyngeal swab specimens using real time RT-PCR. 194 (81.5%) of the serums were detected to be antibody (IgM and/or IgG) positive, significantly higher than the positive rate of viral RNA (64.3%). There was no difference in the positive rate of antibodies between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85), whose nucleic acid tests were negative. The antibody positive rates were very low in the first five days after initial onset of symptoms, and then rapidly increased as the disease progressed. After 10 days, the antibody positive rates jumped from below 50% to over 80%. However, the positive rates of viral RNA maintained above 60% in the first 11 days after initial onset of symptoms, and then rapidly decreased. Overall, the suspected patients were most likely infected by SARS-CoV-2. Before the 11th day after initial onset of symptoms, nucleic acid test is key for confirmation of viral infection. The combination of serological assay can greatly improve the diagnostic efficacy. After the 11th day post-disease onset, the diagnosis for viral infection should be majorly dependent on serological assay."],"journal":"Microbes Infect","authors":["Liu, Lei","Liu, Wanbing","Zheng, Yaqiong","Jiang, Xiaojing","Kou, Guomei","Ding, Jinya","Wang, Qiongshu","Huang, Qianchuan","Ding, Yinjuan","Ni, Wenxu","Wu, Wanlei","Tang, Shi","Tan, Li","Hu, Zhenhong","Xu, Weitian","Zhang, Yong","Zhang, Bo","Tang, Zhongzhi","Zhang, Xinhua","Li, Honghua","Rao, Zhiguo","Jiang, Hui","Ren, Xingfeng","Wang, Shengdian","Zheng, Shangen"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425648","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.micinf.2020.05.008","keywords":["sars-cov-2","diagnosis","nucleic acid test","serological assay"],"topics":["Diagnosis"],"weight":1,"_version_":1667252837954879488,"score":341.769}]}